Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma — Shahneen Sandhu (2019) | RDL Network
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma
Nikhil I. Khushalani, Adi Diab, Paolo A. Ascierto, James Larkin, Shahneen Sandhu, Mario Sznol, Henry Koon, Anthony Jarkowski, Ming Zhou, Paul Statkevich, William J. Geese, Georgina V. Long
Florentia Dimitriou, Kenjiro Namikawa, Irene L. M. Reijers, Elizabeth I. Buchbinder, J. Soon, Anne Zaremba, Paweł Teterycz, Meghan J. Mooradian, Emma Armstrong, Yasuhiro Nakamura, Maria Grazia Vitale, Lena Tran, Xue Bai, Clara Allayous, S. Provent-Roy, Alice Indini, Prachi Bhave, Mohamad Farid, Katharina C. Kähler, Inderjit Mehmi, Victoria Atkinson, Oliver Klein, Connor J. Stonesifer,
Inge Marie Svane, Santosh Nair, Igor Puzanov, Caroline Robert, Jessica C. Hassel, Shahneen Sandhu, Anita Vedel Christiansen, Kath Lowery, Kristine Pemberton, Mohammad Al Hajj, Scott J. Diede, E. Ehrnrooth, Alexander M.M. Eggermont
Discussion(0)
No comments yet. Be the first to comment.